Ramat Gan, Israel, October 13, 2026
Pulsenmore Ltd., a medical technology company specializing in patient-operated home ultrasound systems, has appointed David Woods as Chief Commercial Officer (CCO) as it expands its commercial presence in the United States. Announced on October 13, 2026, the appointment accompanies the expansion of the company’s U.S. commercial team and supports its strategy to increase adoption of remote prenatal ultrasound technology. Woods brings more than 25 years of medical technology leadership experience, including his most recent role as CCO at Creo Medical and previous senior executive positions at PENTAX Medical, where he served as President and CEO of PENTAX Medical Americas. Pulsenmore is working to make prenatal monitoring more accessible by enabling pregnant women to perform ultrasound scans at home, with remote interpretation by healthcare professionals. Following U.S. Food and Drug Administration (FDA) De Novo authorization for its home prenatal ultrasound system, the company has launched U.S. commercial operations and established a strategic collaboration with Ouma Health. The appointment marks another step in its efforts to strengthen commercial execution and expand access to technology-enabled maternal healthcare.
David Woods Brings Extensive MedTech Leadership Experience
Woods joins Pulsenmore at a time when the company is focused on building its U.S. commercial organization and increasing the adoption of its home ultrasound platform. His experience across medical technology businesses includes commercial leadership, market development and executive management. At Creo Medical, he most recently served as Chief Commercial Officer, while his earlier responsibilities at PENTAX Medical included leading its Americas business as President and CEO. This background is expected to support Pulsenmore as it develops relationships with healthcare providers, distribution partners and other stakeholders in the U.S. maternal healthcare market. Commercial adoption of medical technology requires more than regulatory authorization; companies must also establish effective sales channels, demonstrate practical value to healthcare systems and support clinicians in integrating products into existing care pathways. Woods’ appointment reflects Pulsenmore’s emphasis on strengthening these capabilities as it moves from market entry toward broader commercialization. The company has also expanded its U.S. commercial team, although it has not disclosed specific staffing numbers or financial targets associated with the expansion. The leadership appointment is intended to support sustainable growth, rather than representing a new product clearance or a clinical study result.
Home Ultrasound Technology Expands Prenatal Monitoring
Pulsenmore develops patient-operated ultrasound systems designed to bring selected ultrasound examinations into the home environment. Its prenatal technology enables pregnant women to perform scans using a dedicated device, with the resulting information made available for remote assessment by healthcare professionals. The approach is intended to complement conventional prenatal care by helping providers extend monitoring beyond traditional clinical settings when appropriate. Remote ultrasound technology may be particularly relevant for patients who face travel difficulties, live far from healthcare facilities or need additional monitoring within a clinician-directed care plan. However, home scanning does not replace all in-person prenatal examinations, and decisions about its use must follow the system’s authorized indications and clinical protocols. The company’s U.S. commercial launch followed FDA De Novo authorization, which provides a regulatory pathway for certain novel medical devices without a legally marketed predicate device. Pulsenmore has also entered a strategic collaboration with Ouma Health, supporting its efforts to introduce remote prenatal care solutions into the U.S. healthcare market. The long-term impact will depend on provider adoption, reimbursement arrangements, patient usability and evidence that the technology can be integrated safely and effectively into maternity care workflows.
Advertisement
U.S. Expansion Targets Rural and Underserved Communities
Pulsenmore sees opportunities to expand access to maternal healthcare, particularly in rural and underserved communities where access to prenatal services may be limited by distance, staffing shortages or infrastructure challenges. The company is exploring opportunities connected with the U.S. federal Rural Health Transformation Program (RHTP), which supports state-led initiatives intended to improve rural healthcare access, including maternal health services and technology-enabled care. Pulsenmore has not announced a specific award or confirmed funding through this program, so any future commercial benefit remains uncertain. Nevertheless, policy attention to rural healthcare creates a potential environment for technologies that support remote assessment and more connected care delivery. CEO and founder Dr. Elazar Sonnenschein said the company views the U.S. market as an important growth opportunity and that expanding its commercial team reflects its commitment to turning that opportunity into sustainable business development. Woods also emphasized the potential for home ultrasound to make maternal care more accessible and connected. Future growth will depend on market adoption, partnerships, reimbursement and operational execution, alongside continued compliance with applicable medical-device requirements.
Pulsenmore’s appointment of David Woods highlights the company’s focus on commercial leadership as it expands its remote maternal healthcare business in the United States. By combining experienced MedTech leadership with home-based ultrasound technology, the company aims to broaden access to prenatal monitoring and strengthen collaboration between patients and healthcare professionals. Its progress will be measured by how effectively the technology is adopted in clinical practice and whether it can deliver practical value across diverse maternity care settings.
Source: Pulsenmore press release
